Last updated on December 2019

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

Brief description of study

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection

Clinical Study Identifier: NCT04003103

Find a site near you

Start Over

Research Centers of America, LLC ( Site 0007)

Hollywood, FL United States
  Connect »